Scientific Reports (Feb 2022)

Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan

  • Ko Ko,
  • Kazuaki Takahashi,
  • Shintaro Nagashima,
  • Bunthen E,
  • Serge Ouoba,
  • Md Razeen Ashraf Hussain,
  • Tomoyuki Akita,
  • Aya Sugiyama,
  • Takemasa Sakaguchi,
  • Hidetoshi Tahara,
  • Hiroki Ohge,
  • Hideki Ohdan,
  • Tatsuhiko Kubo,
  • Nobuhisa Ishikawa,
  • Toshiro Takafuta,
  • Yoshiki Fujii,
  • Michi Mimori,
  • Fumie Okada,
  • Eisaku Kishita,
  • Kunie Ariyoshi,
  • Masao Kuwabara,
  • Junko Tanaka

DOI
https://doi.org/10.1038/s41598-022-04952-2
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 10

Abstract

Read online

Abstract This study aimed to develop the feasible and effective universal screening strategy of the notable SARS-CoV-2 variants by Sanger Sequencing Strategy and then practically applied it for mass screening in Hiroshima, Japan. A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.). The targeted spike region is amplified by nested RT-PCR using in-house designed primer set hCoV-Spike-A and standard amplification protocol. Additionally, randomly selected 96 samples were also amplified using primer sets hCoV-Spike-B and hCoV-Spike-C. The negative amplified samples were repeated for second attempt of amplification by volume-up protocol. Thereafter, the amplified products were assigned for Sanger sequencing using corresponding primers. The positive amplification rate of primer set hCoV-Spike-A, hCoV-Spike-B and hCoV-Spike-C were 87.3%, 83.3% and 93.8% respectively for standard protocol and increased to 99.6%, 95.8% and 96.9% after second attempt by volume-up protocol. The readiness of genome sequences was 96.9%, 100% and 100% respectively. Among 48 mutant isolates, 26 were B.1.1.7 (Alpha), 7 were E484K single mutation and the rest were other types of mutation. Moreover, 5 cluster cases with single mutation at N501S were firstly reported in Hiroshima. This study indicates the reliability and effectiveness of Sanger sequencing to screen large number of samples for the notable SARS-CoV-2 variants. Compared to the Next Generation Sequencing (NGS), our method introduces the feasible, universally applicable, and practically useful tool for identification of the emerging variants with less expensive and time consuming especially in those countries where the NGS is not practically available. Our method allows not only to identify the pre-existing variants but also to examine other rare type of mutation or newly emerged variants and is crucial for prevention and control of pandemic.